Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
odanacatib (formerly MK-0822)
print preview
bookmark
share with colleague
General Information
Company
Merck & Co. Inc.
Description
Cathepsin K inhibitor
Molecular Target
Cathepsin K
Mechanism of Action
Cathepsin K inhibitor
Latest Stage of Development
Phase III
Indication
Osteoporosis
Partner
Quest Diagnostics Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information